Alzamend Neuro (ALZN)

Executive Summary

Alzamend Neuro is a clinical-stage biopharmaceutical company developing novel therapies for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD. Its lead asset, AL001, is an ionic lithium formulation designed to enhance lithium's efficacy while reducing toxicity, targeting Alzheimer's and psychiatric indications. A Phase 1/2 study in Alzheimer's patients has been completed, and a Phase 1 pharmacokinetic trial in healthy volunteers concluded in December 2025. The company also has ALZN002, an autologous dendritic cell vaccine for Alzheimer's, currently in a Phase 1/2 study expected to complete in 2028. With a market cap under $5 million, Alzamend is a high-risk, early-stage opportunity. Upcoming catalysts include full data readouts from the AL001 PK trial and potential initiation of Phase 2 studies, which could serve as proof-of-concept for the platform.

Upcoming Catalysts (preview)

• Q2 2026Full data readout from AL001 Phase 1 PK trial90% success
• Q4 2026Initiation of Phase 2 trial for AL001 in Alzheimer's disease50% success
• Q2 2027Interim data from ALZN002 Phase 1/2 vaccine trial30% success